Company: SHPH
Filing Date: 2025-03-05
Form Type: S-1/A
Source: 0001493152-25-009106
Chunk: 31

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-03-05
Form: S-1/A
Chunk 31
---
 even if new information becomes available in the future.

<div align='center'>MARKET AND INDUSTRY DATA AND FORECASTS</div>

We obtained the industry and market data used throughout this prospectus from our own internal estimates and research, as well as from independent market research, industry and general publications and surveys, governmental agencies, publicly available information and research, surveys and studies conducted by third parties. Internal estimates are derived from publicly available information released by industry analysts and third- party sources, our internal research and our industry experience, and are based on assumptions made by us based on such data and our knowledge of our industry and market, which we believe to be reliable and reasonable. In some cases, we do not expressly refer to the sources from which this data is derived. In addition, while we believe the industry and market data included in this prospectus or incorporated by reference in this prospectus is reliable and based on reasonable assumptions, such data involve material risks and other uncertainties and are subject to change based on various factors, including those discussed in the section entitled “ Risk Factors” and “Special Note Regarding Forward-Looking Statements.” These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties or by us.

<div align='center'>USE OF PROCEEDS</div>

We estimate that the net proceeds from this offering, after deducting underwriting fees and estimated offering expenses payable by us, will be approximately $5,470,000 million (based on an assumed public offering price of $0.60 per share of common stock, which was the last reported sales price of our common stock on Nasdaq on February 26, 2025, and assuming that all shares of common stock are sold). We intend to use the net proceeds from this offering to fund our Phase II clinical trial for our lead product candidate, including a revised work order for $2.8 million in payments to Theradex Systems, Inc., the CROs supporting our Phase II clinical trials for our radiation sensitizer Ropidoxuridine, and for working capital and general corporate purposes. In addition, we may use up to $2.0 million for marketing and advertising services to communicate information about the Company to the financial community. We presently work with two IR/PR firms and are planning to engage an additional firm to bolster the Company’s marketing and advertising outreach.

The expected use of net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future